Overview

Today Novo Nordisk is Denmark's largest industrial enterprise and one of the most highly valued companies in the world. The company is a global leader in pharmaceuticals for the treatment of diabetes, hemophilia disorders, and obesity, and it has positioned itself at the forefront with regard to social responsibility, environmental protection, and sustainability. For the first time, this book tells the whole story of a basement business that was built into a global pharmaceutical company. It all began in 1922, when insulin came to Denmark and inspired the establishment of two companies, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium. After many years of fierce rivalry, the two companies merged in 1989 in order to be able to survive in global competition. Soon after, years of merger negotiations brought Novo Nordisk to the brink of moving out of Denmark. The story of Novo Nordisk is a story of groundbreaking research and big bets but also of setbacks and crises. A story of strong leaders and personalities but also of family struggles and company infighting. The book is based on full and unhindered access to the company's archives.

Full Product Details

Author:   Kurt Jacobsen
Publisher:   Gad
Imprint:   Gad
Weight:   2.098kg
ISBN:  

9788712073901

ISBN 10:   8712073903
Pages:   520
Publication Date:   31 January 1970
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Temporarily unavailable  
The supplier advises that this item is temporarily unavailable. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out to you.

Table of Contents

"Preface Prologue Chapter 1 Insulin comes to Denmark Chapter 2 Nordisk Insulin Laboratorium Chapter 3 Novo Terapeutisk Laboratorium Chapter 4 The world economic crisis and pancreas controversies Chapter 5 The Hagedorn era Chapter 6 The German occupation and a shortage of glands Chapter 7 German insulin demands and a Danish legal showdown Chapter 8 From war to the postwar age Chapter 9 The succession to a throne and internal struggles Chapter 10 Detergent enzymes and an American decline Chapter 11 Cooperation or a merger? Chapter 12 Sleeping Beauty awakens Chapter 13 An initial public offering and a generational shift Chapter 14 The race for human insulin Chapter 15 Nordisk Gentofte A/S Chapter 16 The merger that created Novo Nordisk A/S Chapter 17 New markets in the east and new rules in the west Chapter 18 Fusion or stand-alone Chapter 19 From merger negotiations to splitting up Chapter 20 The triple bottom line Chapter 21 The firm, fusions, and the foundation Chapter 22 Successes, disappointments, and Victoza Chapter 23 Gains and setbacks Chapter 24 New management and a ""wonder drug"" Chapter 25 From insulin producer to broad pharmaceutical company Sources, literature, and illustrations Notes Index of names"

Reviews

Author Information

Kurt Jacobsen, dr. phil., is a professor of history at Copenhagen Business School. He has published a series of books on some of Denmark's large companies, including Haldor Topsøe, Lundbeck, and GN, and on the Danish health-care system as well as biographies on the business leader and politician Alexander Foss and the politician Aksel Larsen.

Tab Content 6

Author Website:  

Countries Available

All regions